Who owns Alector, Inc.?
The parent company, the largest shareholders that report their holdings, the funds that own Alector, Inc. and what its insiders traded, each from the filing that states it.
The short answer
Alector, Inc. is a listed company: its shares trade on Nasdaq, so it is owned by its shareholders.
137 institutional investors that report to the SEC on Form 13F held 63.8% of its shares on Sep 30, 2026.
The largest of them was BVF Inc/il with 6.75%, followed by TCG Crossover Management, LLC (6.72%) and BlackRock, Inc. (5.17%).
112 mutual funds held 12.1% of the company in their latest reports (the newest of Jul 31, 2026); the largest position was Vanguard Total Stock Market Index Fund's.
In the last 12 months its insiders reported no purchases and 21 sales worth $1 M on SEC Form 4.
Newest figure: Sep 30, 2026.
Holdings reported on SEC Form 13F for the quarter ended Sep 30, 2026: 137 holders, 63.8% of the shares together.
| # | Holder | Of the shares | Value | Shares | Change in the quarter |
|---|---|---|---|---|---|
| 1 | BVF Inc/il | 6.75% | $19 M | 10.0 M | new |
| 2 | TCG Crossover Management, LLC | 6.72% | $19 M | 10.0 M | 0.0% |
| 3 | BlackRock, Inc. | 5.17% | $14 M | 7.7 M | -1.9% |
| 4 | Acadian Asset Management LLC | 3.00% | $8 M | 4.5 M | +1.1% |
| 5 | Nantahala Capital Management, LLC | 2.90% | $8 M | 4.3 M | -50.0% |
| 6 | Kynam Capital Management, LP | 2.89% | $8 M | 4.3 M | +13.1% |
| 7 | Vanguard Capital Management LLC | 2.69% | $7 M | 4.0 M | +0.0% |
| 8 | Merck & Co., Inc. | 2.38% | $7 M | 3.5 M | 0.0% |
| 9 | Millennium Management LLC | 2.05% | $6 M | 3.0 M | +53.1% |
| 10 | Vanguard Portfolio Management LLC | 1.80% | $5 M | 2.7 M | -5.1% |
As of Sep 30, 2026
How ownership moved#
Institutions held 63.8% of Alector, Inc. at Sep 30, 2026, down 22.02 points from Jun 30, 2026; 4 fewer institutions.
| Quarter end | Institutions | Share of the company | Shares bought | Shares sold | Positions opened | Positions closed |
|---|---|---|---|---|---|---|
| Sep 30, 2026(still being filed) | 137 | 63.8% | 14.0 M | 12.9 M | 15 | 19 |
| Jun 30, 2026 | 141 | 85.8% | 15.2 M | 3.3 M | 14 | — |
| Mar 31, 2026 | 137 | 79.6% | — | — | — | — |
| Dec 31, 2025 | 128 | 76.0% | — | — | — | — |
| Sep 30, 2025 | 146 | 68.6% | — | — | — | — |
| Jun 30, 2025 | 135 | 69.7% | — | — | — | — |
| Mar 31, 2025 | 141 | 72.6% | — | — | — | — |
| Dec 31, 2024 | 148 | 73.3% | — | — | — | — |
| Sep 30, 2024 | 159 | 74.1% | — | — | — | — |
| Jun 30, 2024 | 158 | 74.7% | — | — | — | — |
| Mar 31, 2024 | 155 | 76.8% | — | — | — | — |
| Dec 31, 2023 | 145 | 66.3% | — | — | — | — |
| Sep 30, 2023 | 144 | 75.2% | — | — | — | — |
| Jun 30, 2023 | 141 | 69.7% | — | — | — | — |
| Mar 31, 2023 | 142 | 68.7% | — | — | — | — |
| Dec 31, 2022 | 152 | 65.6% | — | — | — | — |
| Sep 30, 2022 | 164 | 65.0% | — | — | — | — |
| Jun 30, 2022 | 149 | 64.1% | — | — | — | — |
| Mar 31, 2022 | 161 | 66.3% | — | — | — | — |
| Dec 31, 2021 | 163 | 66.4% | — | — | — | — |
| Sep 30, 2021 | 140 | 63.9% | — | — | — | — |
Bought most, quarter to Sep 30, 2026
- Millennium Management LLC+1.1 M
- Kynam Capital Management, LP+500,000
- Marshall Wace, LLP+375,202
- Goldman Sachs Group Inc+357,726
- Mackenzie Financial Corp+351,393
- LMR Partners LLP+250,000
- Bank Of America Corp /de/+79,044
- Renaissance Technologies LLC+75,983
Sold most
- Nantahala Capital Management, LLC−4.3 M
- Balyasny Asset Management L.P.−3.0 M
- FMR LLC−1.4 M
- 683 Capital Management, LLC−790,000
- Cantor Fitzgerald, L. P.−470,984
- AQR Capital Management LLC−415,486
- Jacobs Levy Equity Management, Inc−374,083
- ADAR1 Capital Management, LLC−368,743
New positions (shares held)
- BVF Inc/il10.0 M
- Empowered Funds, LLC115,000
- Employees Retirement System of Texas99,803
- Los Angeles Capital Management LLC67,837
- Tudor Investment Corp Et Al40,356
- Dynamic Technology Lab Private Ltd29,958
- Walleye Capital LLC29,142
- Axq Capital, LP20,328
Insiders' open-market purchases (up) and sales (down), by quarter
112 funds held 12.1% of the company in their latest reports. Fund holdings are part of what their managers report on Form 13F, so do not add the two.
| Fund | Manager | Country | Of the company | Value | Report of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | The Vanguard Group, Inc. | 🇺🇸 | 1.91% | $6 M | Jun 30, 2026 |
| iShares Russell 2000 ETF | BlackRock Fund Advisors | 🇺🇸 | 1.71% | $5 M | Jun 30, 2026 |
| Select Biotechnology Portfolio | Fidelity Management & Research Company LLC | 🇺🇸 | 0.93% | $3 M | May 31, 2026 |
| Vanguard Extended Market Index Fund | The Vanguard Group, Inc. | 🇺🇸 | 0.69% | $2 M | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | BlackRock Fund Advisors | 🇺🇸 | 0.55% | $2 M | Jun 30, 2026 |
As of Jul 31, 2026
- Purchases
- 0
- Sales
- 21
- Bought
- $0 M
- Sold
- $1 M
Questions and answers#
Who owns Alector, Inc.?
Alector, Inc. is a listed company: its shares trade on Nasdaq, so it is owned by its shareholders. 137 institutional investors that report to the SEC on Form 13F held 63.8% of its shares on Sep 30, 2026. The largest of them was BVF Inc/il with 6.75%, followed by TCG Crossover Management, LLC (6.72%) and BlackRock, Inc. (5.17%).
Who is the largest shareholder of Alector, Inc.?
Among investors that file SEC Form 13F, BVF Inc/il was the largest on Sep 30, 2026, with 6.75% of the shares. Founders, executives and other people who hold shares in their own name report them on SEC Forms 3, 4 and 5 and in the proxy statement, not on Form 13F, so they are not in this ranking.
How much of Alector, Inc. do institutional investors own?
137 institutional investors that report to the SEC on Form 13F held 63.8% of its shares on Sep 30, 2026.
Which mutual funds own Alector, Inc.?
112 mutual funds held 12.1% of the company in their latest reports (the newest of Jul 31, 2026); the largest position was Vanguard Total Stock Market Index Fund's. Funds' holdings are part of what their managers report on Form 13F, so the two shares overlap.
More about Alector, Inc.#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M